Combination of ALDH2 inhibition and PD‐1 blockade, which increases TILs infiltration in tumor and prevents immune evasion, represents a novel strategy to potentiate immunotherapy in CRC patients with ALDH2 overexpression or heavy alcohol drinking history. The gene discussed is ALDH2; the disease is colorectal carcinoma.